Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $114

Benzinga Newsdesk www.benzinga.com Negative 92.1%

Neg 92.1% Neu 0% Pos 0%

Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:BNTX) with a Overweight and lowers the price target from $115 to $114.